Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy (R-Louisiana) recently released the results of an investigation into the 340B Drug Pricing Program. Here are four key figures from the report.
The 340B Drug Pricing Program has grown significantly since it was esatablished in 1994. In recent years, the program has come under fire from critics who say that participating health systems fail to pass benefits on to low-income patients.
How big has the program grown? A recent report from Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy (R-Louisiana), the result of a two-year-long investigation, revealed how much is spent through the program and how many health systems are benefitting from it.
Check out the infographic below to learn more or read more here.
Luke Gale is the revenue cycle editor for HealthLeaders.
KEY TAKEAWAYS
The 340B Drug Pricing Program has grown significantly since it was established in 1994, drawing increased scrutiny as it has expanded.
More than $66 billion dollars were spent on outpatient drugs through the program in 2023.